CN1169543C - Fat reducing health care product and its preparing method - Google Patents
Fat reducing health care product and its preparing method Download PDFInfo
- Publication number
- CN1169543C CN1169543C CNB011215461A CN01121546A CN1169543C CN 1169543 C CN1169543 C CN 1169543C CN B011215461 A CNB011215461 A CN B011215461A CN 01121546 A CN01121546 A CN 01121546A CN 1169543 C CN1169543 C CN 1169543C
- Authority
- CN
- China
- Prior art keywords
- blood fat
- fat reducing
- health product
- present
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a health-care product for lowering blood fat, which comprises the raw materials of the following weight part: 1 part of ginkgo, 1 to 3 parts of astragalus root, 0.7 to 1.5 parts of ophiopogon root, 0.7 to 1.5 parts of jujube and 0.3 to 1.0 part of licorice root. The product can be obtained by the steps of granulation by using a method of water decoction, drying, sieving, weighing and packaging. The present invention is nontoxic and harmless to human bodies, has the functions of lowering blood fat and blood viscosity, improving the hypercoagulative state of blood, dredging microcirculation, strengthening body's immunity and reducing and reliving hyperlipaemia complications, and has the advantages of simple technology, convenient preparation, low price and stable therapeutic effect.
Description
Technical field
The present invention relates to a kind of health product with effect for reducing blood fat, specifically is herbal mixture health product of feedstock production and preparation method thereof with the Chinese herbal medicine.
Background technology
Hyperlipemia is the common frdquently encountered disease of serious threat human health, is the first disease that jeopardizes the human life.Because the blood fat height causes fat metabolic disturbance, causes the rising of blood viscosity, cardiovascular and cerebrovascular diseases such as cerebral thrombosis, coronary heart disease, hypertension, atherosclerosis appear in middle and advanced stage.
At present, both at home and abroad to the treatment of hyperlipemia mainly based on Western medicine, big as " clofibrate " class medicine treatment side effect, for a long time with infringement liver, kidney and hemocyte; " lipanthyl " though etc. the fibrate lipid-lowering drugs effect for reducing fat good, easily bounce-back after the drug withdrawal and has certain untoward reaction.
Summary of the invention
The purpose of this invention is to provide that a kind of side effect is little, the fat reducing health care product of stable curative effect and preparation method thereof.
Solution of the present invention is based on motherland's medical science to hyperlipemia disease and the pathogenetic understanding of complication and the principle of curing the disease, with reference to the modern pharmacological research achievement, from motherland's medicine treasure-house, filter out tonifying Qi and lifting yang, benefit is defended consolidating superficial resistance, changes blood stasis, pure and impure rushing down, the homologous natural edible-plant medicine of medicated diet, by the theory of Chinese medical science prescription, skim the cream off milk, make its performance reduce exogenous blood fat and increase, promote lipid metabolism, blood lipid level is reduced, and microcirculation improvement reduces, alleviates the pathogenetic effect of hyperlipemia.
Fat reducing health care product parts by weight of the present invention are formed and are included: 1 part of Semen Ginkgo, Radix Astragali 1-3 part, Radix Ophiopogonis 0.7-1.5 part, Fructus Jujubae 0.7-1.5 part, Radix Glycyrrhizae 0.3-1.0 part.
The composition of aforesaid fat reducing health care product parts by weight also includes Rhizoma Chuanxiong 0.6-2.4 part, Cordyceps 0.7-1.5 part.
Preparation method of the present invention is as follows:
Above-mentioned proportion of composing is taken by weighing, and the adding distil water amount is about 8-10 a times of its gross weight, decocts twice, being 1.5-2.5 hour for the first time, is 1.0-1.5 hour for the second time, collecting decoction, filter, leave standstill cold preservation, add 6-18 dextrin doubly, add ethanol and make soft material, make granule, drying is sieved, and weighs, packing promptly gets product.
The present invention has following advantage:
1. to select the homologous natural edible medicine of medicated diet for use be raw material in the present invention, and each component meets the pharmaceutical control law regulation.Utilize the comprehensive function of the Chinese medicine of respectively distinguishing the flavor of, the treatment hyperlipemia does not have chemical sweeting agent, and is nontoxic to human body.
2. taking convenience of the present invention meets the regulation of state food health legislation.
3. the present invention contains abundant flavonoids, and content is 1.2%-3.0%, and flavone compound has blood fat reducing, it is sticking to fall blood, improves high blood coagulation state, the mediation microcirculation, and enhancing human body immunity reduces, alleviates the effect of hyperlipoidemia complication.
4. technology of the present invention is simple, easy to make, cheap, and having ready conditions becomes popular health product.And for Western medicine, health product toxic and side effects of the present invention is little, stable curative effect.
In order to inquire into effect for reducing fat of the present invention, we adopt the hyperlipidemia rats model, are tester with Western medicine fenofibrate, Chinese medicine Semen Ginkgo extrac, have carried out pharmaceutical research.After the hyperlipidemia rats model moulding success, next day, we begin to carry out the effect experiment research of health product of the present invention.1st, 2 groups begin to irritate the stomach normal saline, 3rd, irritate these health product of stomach Chinese medicinal powder low dose, middle dosage, heavy dose (dosage is respectively 2.2g/kg.d, 4.4g/kg.d, 8.8g/kg.d) for 4,5 groups, irritate stomach Semen Ginkgo extrac (40mg/kg.d) for the 6th group, irritate stomach fenofibrate (100mg/kg.d) (wherein the 3rd, 5 group dosage is respectively 10 times, 40 times of people's consumption, and the dosage of all the other groups is 20 times of people's consumption) for the 7th group.Irritate the stomach amount and be 2-4ml, every day 1 time.Overnight fasting after 25 days (12h) is measured blood lipids index next day, and the result is as shown in table 1.
The influence of table 1 pair hyperlipidemia rats blood lipid level (X ± S)
Group example number dosage serum cholesterol meansigma methods serum triglycerides meansigma methods
(only) be (mmol/L) (mmol/L)
Normal control (1) 8-5.63 ± 0.71 1.61 ± 0.18
Hyperlipidemia model (2) 8-9.21 ± 1.05* 2.52 ± 0.54*
These health product
★(3) 8 2.2g/kg.d 5.01 ± 0.92
#1.44 ± 0.26
#
(4) 8 4.4g/kg.d 3.10±0.77
# 1.32±0.25
#
(5) 8 8.8g/kg.d 4.60±0.74
# 1.28±0.44
#
Semen Ginkgo extrac (6) 8 40mg/kg.d. 4.95 ± 0.83
#1.39 ± 0.47
#
Fenofibrate (7) 8 100mg/kg.d. 4.93 ± 0.71
#1.38 ± 0.27
#
* with the normal control group significant difference (P＜0.01) is arranged relatively
#With high fat group significant difference (P＜0.01) is arranged relatively
★Use the Chinese medicine of the five flavours extract powder.
By table 1 as seen, three dosage groups of these health product Chinese medicinal powder, Semen Ginkgo extrac group and fenofibrate group and high fat group compare, and serum cholesterol, triglyceride are tending towards reducing, and all have the difference (P＜0.01) of highly significant on the statistics.The result shows that these health product, Semen Ginkgo extrac and fenofibrate all have effect for reducing blood fat, and these health product effect for reducing blood fat is better than Western medicine fenofibrate and Chinese medicine Semen Ginkgo extrac, demonstrates stronger effect for reducing blood fat.
For showing the therapeutic effect of fat reducing health care product to hyperlipemia, the present invention selects medical history, the state of an illness, age, hyperlipidemia patient 25 examples that sex and former Therapeutic Method are suitable are matched group, reach the outpatient service of intracardiac section from being in hospital and select 34 routine hyperlipidemia patients, press the hyperlipemia diagnostic criteria that Ministry of Public Health bureau of drug administration formulated in 1994, the adult hyperlipidemia patient of making a definite diagnosis, on the basis of dietetic therapy and medicine (oral fenofibrate) treatment, serum cholesterol content 〉=5.98mmol/L or content of triglyceride 〉=1.54mmol/L person are the object of observation on an empty stomach, wherein male 19 examples, woman's 15 examples, age 28-54 year, course of disease half a year-15 year.Test group: on the basis of former medicine treatment, the lipid lowerers of stopping using is taken medicine of the present invention.Matched group: blood fat reducing treatment routinely, wherein fat-reducing medicament usage, consumption and test group are complementary, and fat-reducing medicament adopts fenofibrate.Adopt same procedure to make regular check on fasting plasma lipid, observed nine months, three months is a course of treatment, totally three courses of treatment.
Instructions of taking: 20 grams/time, day clothes 3 times, ante cibum, boiled water was taken after mixing it with water.Clinical test results such as table 2.
Table 2 is taken health product front and back lipid lowerers consumption of the present invention and the average concentration change of blood fat
| Case load | Fenofibrate consumption (mg/d) | Serum cholesterol meansigma methods (mmol/L) | Serum triglycerides meansigma methods (mmol/L) | ||||
| Before | After | Before | After | Before | After | ||
| Test group matched group t p | 34 25 | 0 300 | 0 300 | 6.75±0.94 6.82±1.03 0.33 ＞0.05 | 5.42±0.87 6.55±0.91 4.83 ＜0.05 | 2.37±1.05 2.42±0.64 0.23 ＞0.05 | 1.85±0.70 2.31±0.89 2.14 ＜0.05 |
As can be seen from Table 2, serum cholesterol and triglyceride do not have significant difference before two groups of tests, but after test group takes health product of the present invention, do not use any other lipid lowerers, can reach the blood fat reducing purpose.
Table 3 liang group blood fat reducing curative effect relatively
| Group | The example number | Produce effects/% | Effectively/% | Invalid/% | Total effective rate/% | |
| Serum cholesterol | Treatment group matched group | 34 25 | 7(20.6) 6(24.0) | 18(52.9) 11(44.0) | 9(26.5) 8(32.0) | 73.5 68.0 |
| Triglyceride | Treatment group matched group | 34 25 | 5(14.7) 3(12.0) | 19(55.8) 13(52.0) | 10(29.5) 9(36.0) | 70.5 64.0 |
The hyperlipemia disease criterion of therapeutical effect that Ministry of Public Health bureau of drug administration formulated in 1994:
Produce effects: reach following arbitrary index person: serum cholesterol decline 〉=20% or serum triglycerides 〉=20%.
Effectively: reach following arbitrary index person: serum cholesterol decline 10～19% or serum triglycerides descend 10～19%.
It is invalid: as not reach efficiency index.
We add up blood fat reducing curative effect of the present invention, the results are shown in Table 3.Test statistics shows: with fat reducing health care product of the present invention 34 routine hyperlipemia disease patients are done therapeutic test, that falls that hypercholesterolemia obtains significant curative effect accounts for 20.6%, substantially effectively accounts for 52.9%, and invalid accounts for 26.5%, and total effective rate reaches 73.5%; That falls that high triglyceride disease obtains significant curative effect accounts for 14.7%, substantially effectively accounts for 55.8%, and invalid accounts for 29.5%, and total effective rate reaches 70.5%.
The specific embodiment
Embodiment 1
Get Semen Ginkgo 20g, Radix Astragali 20g, Radix Ophiopogonis 15g, Fructus Jujubae 15g, Radix Glycyrrhizae 10g, adding distil water decocts twice, is respectively 1.5 hours, 1 hour, collecting decoction filters, and leaves standstill, cold preservation adds 6 times dextrin, adds ethanol and makes soft material (hands is pinched can be agglomerating, light pressure is then loose and is advisable), make granule, drying, sieve, weigh, packing, promptly.
Embodiment 2
Get Semen Ginkgo 30g, Radix Astragali 45g, Radix Ophiopogonis 30g, Fructus Jujubae 30g, Radix Glycyrrhizae 20g, adding distil water decocts twice, is respectively 2 hours, 1 hour, collecting decoction filters, and leaves standstill, cold preservation adds 10 times dextrin, adds ethanol and makes soft material (hands is pinched can be agglomerating, light pressure is then loose and is advisable), make granule, drying, sieve, weigh, packing, promptly.
Embodiment 3
Get Semen Ginkgo 40g, Radix Astragali 80g, Radix Ophiopogonis 40g, Fructus Jujubae 50g, Radix Glycyrrhizae 30g, adding distil water decocts twice, is respectively 2 hours, 1.5 hours, collecting decoction filters, and leaves standstill, cold preservation adds 12 times dextrin, adds ethanol and makes soft material (hands is pinched can be agglomerating, light pressure is then loose and is advisable), make granule, drying, sieve, weigh, packing, promptly.
Embodiment 4
Get Semen Ginkgo 50g, Radix Astragali 120g, Radix Ophiopogonis 60g, Fructus Jujubae 60g, Radix Glycyrrhizae 40g, Rhizoma Chuanxiong 30g, Cordyceps 40g, adding distil water decocts twice, is respectively collecting decoction 2.5 hours, 1 hour, filter, leave standstill cold preservation, the dextrin that adds 15 times adds ethanol and makes soft material (hands is pinched can be agglomerating, and light pressure is then loose and is advisable), make granule, drying is sieved, weigh, packing, promptly.
Embodiment 5
Get Semen Ginkgo 50g, Radix Astragali 150g, Radix Ophiopogonis 80g, Fructus Jujubae 80g, Radix Glycyrrhizae 50g, Rhizoma Chuanxiong 100g, Cordyceps 50g, adding distil water decocts twice, is respectively collecting decoction 2.5 hours, 1.5 hours, filter, leave standstill cold preservation, the dextrin that adds 18 times adds ethanol and makes soft material (hands is pinched can be agglomerating, and light pressure is then loose and is advisable), make granule, drying is sieved, weigh, packing, promptly.
Claims (3)
1. the health product of a blood fat reducing is characterized in that being made by the following weight parts crude drug: 1 part of Semen Ginkgo, Radix Astragali 1-3 part, Radix Ophiopogonis 0.7-1.5 part, Fructus Jujubae 0.7-1.5 part, Radix Glycyrrhizae 0.3-1.0 part.
2. the health product of a kind of blood fat reducing according to claim 1 is characterized in that the weight portion composition of its crude drug also comprises: Rhizoma Chuanxiong 0.6-2.4 part, Cordyceps 0.7-1.5 part.
3. according to the health product of the described a kind of blood fat reducing of claim 1, it is characterized in that preparation method is:
Take by weighing crude drug by above-mentioned weight portion composition, the adding distil water amount is about 8-10 a times of its gross weight, decocts twice, being 1.5-2.5 hour for the first time, is 1.0-1.5 hour for the second time, collecting decoction, filter, leave standstill cold preservation, add 6-18 dextrin doubly, add ethanol and make soft material, make granule, drying is sieved, and weighs, packing promptly gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011215461A CN1169543C (en) | 2001-06-18 | 2001-06-18 | Fat reducing health care product and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011215461A CN1169543C (en) | 2001-06-18 | 2001-06-18 | Fat reducing health care product and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1391923A CN1391923A (en) | 2003-01-22 |
| CN1169543C true CN1169543C (en) | 2004-10-06 |
Family
ID=4664521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011215461A Expired - Fee Related CN1169543C (en) | 2001-06-18 | 2001-06-18 | Fat reducing health care product and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1169543C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109567166A (en) * | 2018-12-25 | 2019-04-05 | 盐城工学院 | A kind of fermented tcm health care product and the preparation method and application thereof reducing cholesterol |
-
2001
- 2001-06-18 CN CNB011215461A patent/CN1169543C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1391923A (en) | 2003-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461896B (en) | Chinese medicinal composition assistant for reducing blood fat and preparation method thereof | |
| CN1839944A (en) | Granular composition for reducing blood fat and process for producing the same | |
| WO2009149585A1 (en) | Compositions for reducing blood glucose level and uses thereof | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN1053375C (en) | Chinese medicine preparation for hepatosis | |
| CN101537160B (en) | Health product for toxicant elimination and beauty maintenance | |
| CN1939506A (en) | Vision-improving preparation with depressor, blood-sugar and blood-fat lowering functions and its making method | |
| CN101279034B (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN102178798A (en) | Preparation for reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases | |
| CN1169543C (en) | Fat reducing health care product and its preparing method | |
| CN102133273A (en) | Traditional Chinese medicine lipid-lowing and aperient capsule and preparation method thereof | |
| CN102018852A (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN1440804A (en) | Antilipemic Chinese medicine | |
| CN1857599A (en) | Medicine for lowering blood sugar, blood fat and blood pressure, raising blood flow rate and raising immunity and its preparing method | |
| CN103007159A (en) | Chinese medicinal preparation for correcting pancreas islet function | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN1183936C (en) | Medicine for treating hypertension and method for preparing medicinal tea thereof | |
| CN101732657A (en) | Medicine composition | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN1843460A (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN1231196A (en) | Capsule for promoting male sexual function and preparation process | |
| CN1279961C (en) | Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |